Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai General Healthy Information and Technology Co., Ltd. (605186.SS)
Shanghai, CN
Shanghai General Healthy Information and Technology Co., Ltd. (SGHIT) delivers a range of advanced solutions to the healthcare sector in China. These encompass automated pharmaceutical logistics, cutting-edge information technology, and intelligent, mobile medical applications. Its core product portfolio features the "Smart Pharmacy Project," an integrated hardware and software system designed for intelligent medication management. Another key offering is the "Intelligent Static Distribution Center Project," a sophisticated system for the configuration and oversight of intravenous medications. Additionally, the "Intelligent Drug Consumables Management Project" provides specialized oversight for various pharmaceutical supplies, including controlled substances and high-value medical items. Established in 2014, SGHIT operates from its headquarters in Shanghai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.07% | +24.16% | +26.32% | +10.85% | +14.73% | +25.29% | +21.34% | -40.47% | +30.82% | +20.39% | +20.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+8.5% Q1'26: -1.4% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-4.2% Q1'26: -16.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+12.9% Q1'26: -73.5% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+10.3% ★ Q1'26: +7.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.6% Q1'26: +1.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-1.2% ★ Q1'26: +19.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.26× ★ Q1'26: 6.20× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
489.76M
est: 515.17M (-4.9%)
|
322.36M
est: 659.58M (-51.1%)
|
307.56M
est: 407.00M (-24.4%)
|
318.35M
est: 380.71M (-16.4%)
|
345.49M
est: 412.01M (-16.1%)
|
382.69M
382.69M – 382.69M
-7.1% YoY
|
421.72M
421.72M – 421.72M
+10.2% YoY
|
460.49M
460.49M – 460.49M
+9.2% YoY
|
| EBITDA |
147.25M
est: 162.57M (-9.4%)
|
135.49M
est: 208.14M (-34.9%)
|
73.89M
est: 128.43M (-42.5%)
|
60.30M
est: 120.95M (-50.1%)
|
58.99M
est: 130.89M (-54.9%)
|
121.58M
121.58M – 121.58M
-7.1% YoY
|
133.98M
133.98M – 133.98M
+10.2% YoY
|
146.30M
146.30M – 146.30M
+9.2% YoY
|
| EBIT |
144.02M
est: 151.64M (-5.0%)
|
132.11M
est: 194.15M (-32.0%)
|
69.03M
est: 119.80M (-42.4%)
|
39.79M
est: 113.03M (-64.8%)
|
35.51M
est: 122.32M (-71.0%)
|
113.62M
113.62M – 113.62M
-7.1% YoY
|
125.20M
125.20M – 125.20M
+10.2% YoY
|
136.71M
136.71M – 136.71M
+9.2% YoY
|
| Net Income |
117.62M
est: 130.08M (-9.6%)
|
115.68M
est: 195.12M (-40.7%)
|
60.00M
est: 126.02M (-52.4%)
|
32.52M
est: 126.02M (-74.2%)
|
30.78M
est: 59.62M (-48.4%)
|
67.75M
67.75M – 67.75M
+13.6% YoY
|
84.01M
84.01M – 84.01M
+24.0% YoY
|
101.63M
101.63M – 101.63M
+21.0% YoY
|
| SGA |
42.46M
est: 44.16M (-3.8%)
|
42.98M
est: 56.54M (-24.0%)
|
55.50M
est: 34.89M (+59.1%)
|
70.05M
est: 56.04M (+25.0%)
|
25.48M
est: 60.65M (-58.0%)
|
56.33M
56.33M – 56.33M
-7.1% YoY
|
62.08M
62.08M – 62.08M
+10.2% YoY
|
67.79M
67.79M – 67.79M
+9.2% YoY
|
| EPS |
0.86
est: 0.96 (-10.4%)
|
0.85
est: 1.44 (-41.0%)
|
0.44
est: 0.93 (-52.7%)
|
0.24
est: 0.93 (-74.2%)
|
0.23
est: 0.44 (-47.7%)
|
0.50
0.50 – 0.50
+13.6% YoY
|
0.62
0.62 – 0.62
+24.0% YoY
|
0.75
0.75 – 0.75
+21.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gang Cheng | Executive Deputy GM & Director | — | male |
| Hong Qiu | Deputy GM, Chief Financial Officer, Secretary of the Board of Directors & Director | — | male |
| Jianfeng Luo | Deputy General Manager | — | male |
| Jianwei Dai | Chairman of the Board & GM | — | male |
| Junhua Zhang | Deputy General Manager | — | male |
| Ling Zhao | Deputy GM & Director | — | male |
| Shaodeng Wang | Sales Director & Supervisor | — | male |
| Weiyong Gong | Deputy General Manager | — | male |
| Ying Zhu | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 605186.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
